Activation of PI3K/AKT/mTOR signaling also associates with sorafenib resistance in HCC,251 providing the rationale for the combination of targeting PI3K/AKT/mTOR cascade with sorafenib. This evidence concerns the gene MTOR and hepatocellular carcinoma.